Introduction
In the last decade, scientific research has helped us come a long way in understanding the pathogenesis of cholesterol in coronary artery disease (CAD). We know more precisely the role cholesterol plays in the formation of atherosclerotic plaques and the subsequent plaque rupture that leads to unstable coronary syndromes. Epidemiologic studies suggest that elevated cholesterol levels may not be a risk factor for CAD in the older age group (age 75 and older). Randomized controlled trials (RCTs) evaluating relatively healthy middle-aged adults suggest that lowering cholesterol levels can decrease cardiovascular morbidity and mortality in patients with CAD. However, the generalizability of these findings to seniors may be difficult.
In this article we will examine the evidence from epidemiologic studies and RCTs evaluating the role of cholesterol reduction in preventing CAD and discuss difficulties in generalizing these studies to elderly people.
What do we know from epidemiologic studies?
Five large observational studies [1] [2] [3] [4] [5] have suggested that elevated cholesterol may not be harmful in older people. In the first of these, Ives and colleagues [1] examined 3,874 rural community-dwelling seniors and correlated levels of total serum cholesterol with morbidity and mortality. At two years follow-up, 12.8% of patients with cholesterol levels below 3.9 mmol/L died, compared with 7.3% of those in the group with levels of 5.2-6.2 mmol/L. No increase in any specific causes of mortality was documented. This led to the idea that a low cholesterol level may be a marker identifying individuals with one or more non-cardiac diseases which shorten life expectancy [1] .
Data from the Framingham study also challenged the role of cholesterol-lowering therapy in elderly people. Kronmal et al. [2] examined the relationship between serum total cholesterol levels and mortality by decade of patient age and found a positive relationship between cholesterol and all-cause mortality at age 40, a neutral effect at age 60, and a negative relationship at age 80. These findings suggest that lowering cholesterol in older persons might actually be harmful.
In the third observational study, Krumholz et al. [3] suggested that low cholesterol levels were associated with a higher mortality. This was a longitudinal study of a cohort of community-dwelling older persons ages 65 and older living in the United States. The authors examined a subset of 997 patients from the New Haven, Connecticut cohort within the Established Population for the Epidemiologic Study of the Elderly (EPESE). The mean age of the patients was 78.8 years and 64% were female. Using a multivariate logistic regression model, patients in the lower (<5.2 mmol/L) and upper (>6.2 mmol/L) groups of total cholesterol had overall mortality rates similar to the middle group (5.2-6.2 mmol/L) [3] . Corti et al.
[4] examined the entire EPESE cohort and evaluated 3,904 patients from the three communities participating in the EPESE cohort. They found no effect of total cholesterol upon mortality. The findings of these two studies [3, 4] require further confirmation in other studies of seniors, but have led some to suggest that people in their 70s and beyond should not have their cholesterol measured or treated [6] .
Finally, the most recent epidemiologic study of cholesterol in elderly people suggests that low cholesterol levels may be harmful in seniors. WeverlingRijnsburger et al. [5] followed 724 inhabitants of the Dutch community of Leiden who were 85 years or older for ten years. Patients with lower cholesterol levels died more often from cancer and infection and had a lower median survival rate when compared with those with higher cholesterol levels. The adjusted relative risk (RR) of mortality for the group with cholesterol concentrations >6.4 mmol/L was 0.55 (95% CI 0.42-0.73), suggesting that elevated cholesterol levels were associated with a higher survival [5] .
The results published by Weverling-Rijnsburger et al. [5] need to be interpreted with caution. First, the authors used comparative cholesterol data from the Zutphen study, which involved a birth cohort from 1900 to 1910 in Zutphen, the Netherlands. Although distributions of serum cholesterol from Leiden and Zutphen appear similar, men from Leiden had, on average, lower cholesterol levels [5] . Second, the patients may have been overly selected for the study, since 221 patients (17.6%) died before they could be interviewed and 60 patients (6%) refused to participate. These factors need to be considered when interpreting the results of this study.
These five observational studies [1] [2] [3] [4] [5] suggest that elevated cholesterol may not play a major role in the morbidity and mortality of elderly people and suggest that caution should be observed when treating hypercholesterolaemia in older persons.
What do we know from randomized controlled trials?
In the last few years, several landmark RCTs [7] [8] [9] have extended our knowledge about treating elevated cholesterol in relatively young patients. Each of these large RCTs built upon the results of the Lipid Research Clinics (LRC) study (10), one of the first RCTs to demonstrate a reduction in cardiovascular mortality and non-fatal myocardial infarction (MI) with cholesterol-lowering therapy.
The LRC study was a primary prevention trial and only included patients with no known CAD [10]. The second major primary prevention trial was the West of Scotland Coronary Prevention (WOSCOP) study [7] . Shepherd et al. [7] demonstrated that treating middleaged men with elevated cholesterol levels and no previous MI also decreased cardiovascular mortality and rates of non-fatal MI. These two studies support lipidlowering therapy in patients with hyperlipidaemia and no prior CAD.
Two secondary prevention trials [8, 9] suggest that lowering cholesterol levels prevents recurrent MI and death in patients with CAD. For patients with either a previous MI or exertional angina, the Scandinavian Simvastatin Survival Study (4S) [8] suggests that lowering cholesterol in patients with elevated cholesterol levels decreases overall mortality. Similar results were found with lowering cholesterol in men and women with "average" cholesterol levels post-MI [9] . Both of these secondary prevention studies [8, 9] included men and women over the age of 65. The 4S study included patients up to age 70, with a predefined subgroup analysis for patients over age 60 [8] . This subgroup benefitted equally from the intervention as did the overall group. The Cholesterol And Recurrent Events (CARE) trial [9] studied patients up to age 75; their predefined subgroup of age >60 years had a reduction in major coronary events that was greater than the younger subgroup and comparable to the overall group. Both of these studies found improved survival and decreased incidence of subsequent MI with cholesterol-lowering therapy.
A recent meta-analysis of studies looking at reversing coronary atherosclerotic plaque formation through lipid-lowering therapy confirmed that cardiovascular mortality was decreased with cholesterol-lowering in patients with mild to moderately elevated lipids [11] . Lipid-lowering therapy has also been shown to delay the progression of atherosclerosis in saphenous-vein coronary artery bypass grafts [12] . These studies have consistently demonstrated that hypercholesterolaemia plays an important role in the pathogenesis of CAD and that cholesterol-lowering therapy can favourably alter the course of patients with pre-existing CAD.
Generalizing to seniors
It is uncertain if the information generated from the epidemiologic studies and RCTs we have reviewed can be generalized to seniors.
First, epidemiologic studies rely on sophisticated statistical modelling techniques to adjust for the effect of known prognostic factors on mortality (e.g. diabetes, smoking, hypertension, etc.). However, it is difficult to adequately adjust for all prognostic factors,
